SCYNEXIS (SCYX) Competitors

Molecular Partners (NASDAQ:MOLN) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Which has higher earnings & valuation, MOLN or SCYX?

SCYNEXIS has lower revenue, but higher earnings than Molecular Partners. SCYNEXIS is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	27.55	-$61.39M	-$2.08	-1.85
SCYNEXIS	$3.75M	9.29	-$21.29M	-$0.40	-2.08

Do analysts prefer MOLN or SCYX?

Molecular Partners currently has a consensus target price of $12.00, suggesting a potential upside of 211.28%. Given Molecular Partners' stronger consensus rating and higher probable upside, equities analysts plainly believe Molecular Partners is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
SCYNEXIS	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is MOLN or SCYX more profitable?

Molecular Partners has a net margin of 0.00% compared to SCYNEXIS's net margin of -599.05%. SCYNEXIS's return on equity of -43.04% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-48.58%	-43.74%
SCYNEXIS	-599.05%	-43.04%	-28.21%

Which has more volatility and risk, MOLN or SCYX?

Molecular Partners has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.

Do institutionals & insiders hold more shares of MOLN or SCYX?

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 4.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media favor MOLN or SCYX?

In the previous week, Molecular Partners had 8 more articles in the media than SCYNEXIS. MarketBeat recorded 10 mentions for Molecular Partners and 2 mentions for SCYNEXIS. Molecular Partners' average media sentiment score of -0.02 beat SCYNEXIS's score of -0.24 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Molecular Partners beats SCYNEXIS on 11 of the 17 factors compared between the two stocks.